CD79B and diffuse large B-cell lymphoma: This treatment was able to increase the abundance of both CD19 and CD79b mRNAs (Fig. 3), suggesting that epigenetic silencing does indeed play a role in the lack of expression of CD19 and CD79b in KIS-1 DLBCL cells.